Variance Between Experts and Community Practitioners in the Use of Immune Checkpoint Inhibitors for Advanced Melanoma

This poster, developed in collaboration with noted experts in advanced melanoma, was presented in November 2016 at the Society for Melanoma Research 2016 International Congress in Boston, Massachusetts. The poster highlights an innovative online tool developed to help facilitate therapeutic decision making in advanced melanoma. In the first-line setting for patients with BRAF wild-type disease, experts were more likely to recommend combination checkpoint inhibitor therapy than community practitioners. Similarly, in the first-line setting for patients with BRAF V600 mutant disease, experts preferred checkpoint therapy in comparison to community practitioners who preferred combination targeted therapy. Clinicians who initially chose a therapy choice other than those recommended by the experts indicated that their use of the tool would change their choice of treatment in 52% of cases, demonstrating that online tools can make a substantial difference in clinical decision making.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?